The DOI matches its Crossref record; the references it cites are not checked yet.
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
Open accessAbstract
Cell surface expression levels of GPRC5D, an orphan G protein–coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeutic strategies. The novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, effectively kills GPRC5D+ MM cell lines in the presence of T cells from both healthy donors or heavily pretreated MM patients. In addition, talquetamab has potent anti-MM activity in bone marrow (BM) samples from 45 patients, including those with high-risk cytogenetic aberrations. There was no difference in talquetamab-mediated killing of MM cells from newly diagnosed, daratumumab-naïve relapsed/refractory (median of 3 prior therapies), and daratumumab-refractory (median of 6 prior therapies) MM patients. Tumor cell lysis was accompanied by T-cell activation and degranulation, as well as production of pro-inflammatory cytokines. High levels of GPRC5D and high effector:target ratio were associated with improved talquetamab-mediated lysis of MM cells, whereas an increased proportion of T cells expressing PD-1 or HLA-DR, and elevated regulatory T-cell (Treg) counts were associated with suboptimal killing. In cell line experiments, addition of Tregs to effector cells decreased MM cell lysis. Direct contact with bone marrow stromal cells also impaired the efficacy of talquetamab. Combination therapy with daratumumab or pomalidomide enhanced talquetamab-mediated lysis of primary MM cells in an additive fashion. In conclusion, we show that the GPRC5D-targeting T-cell redirecting bispecific antibody talquetamab is a promising novel antimyeloma agent. These results provide the preclinical rationale for ongoing studies with talquetamab in relapsed/refractory MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Talquetamab (JNJ-64407564), a bispecific IgG4 antibody with a proline, alanine, alanine scaffold designed to minimize Fc-receptor binding, binds to both GPRC5D and CD3 to induce killing of GPRC5D-expressing myeloma cells by means of T-cell recruitment and activation. 14,20”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“GPRC5D expression is enriched in malignant plasma cells and is associated with markers of high-risk myeloma. 13,14,16,19-21”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“GPRC5D expression is enriched in malignant plasma cells and is associated with markers of high-risk myeloma. 13,14,16,19-21”
From Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022) · cites this paper as [20]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Clinical studies have demonstrated the percentages of RRMM patients who responded to talquetamab were 70% (95% CI, 51 to 85) and 64% (95% CI, 48 to 78) at doses of 800 µg and 405 µg per kilogram weekly, respectively. The median duration of response (mDOR) for patients treated with talquetamab at 800 µg and 405 µg per kilogram weekly was 10.2 months and 7.8 months, respectively [216, 217].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [216]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 43 · Cited by 182
Metadata
- Authors
- Verkleij, C. P. M., Broekmans, M. E. C., van Duin, M., Frerichs, K. A., Kuiper, R., de Jonge, A. V., Kaiser, M., Morgan, G., Axel, A., Boominathan, R., Sendecki, J., Wong, A., Verona, R. I., Sonneveld, P., Zweegman, S., Adams, H. C., Mutis, T., & van de Donk, N. W. C. J.
- Affiliations
- Amsterdam University Medical Centers (NL)
- Erasmus MC Cancer Institute, Rotterdam, The Netherlands;
- Erasmus MC Cancer Institute (NL)
- Department of Hematology, Cancer Center Amsterdam, Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands;
- Institute of Cancer Research (GB)
- NYU Langone Health (US)
- Janssen Research & Development, Spring House, PA
- ORCID
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2021-04-23
- Volume
- 5
- Issue
- 8
- Pages
- 2196-2215
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- PMC
- PMC8095149
- OpenAlex
- W3154427589
- Cited by
- 182
- References
- 43
- Citations by year
- 2026: 29 · 2025: 41 · 2024: 58 · 2023: 33 · 2022: 16 · 2021: 5
- FWCI
- 18.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Blood Advances (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Amgen
- Sanofi
- Celgene
- SkylineDx
- International Myeloma Society
- Servier
- Janssen Research and Development
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- talquetamab, GPRC5D, multiple myeloma, bispecific antibodies, G protein-coupled receptors, T cell cytotoxicity, regulatory T cells, PD-1, HLA-DR, mesenchymal stem cells, relapsed/refractory multiple myeloma, effector-to-target ratio, cytokine production
- MeSH terms
- Humans, Lymphocyte Activation, Multiple Myeloma, Antibodies, Bispecific, T-Lymphocytes, Regulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. https://app.cochat.ai/papers/10.1182/bloodadvances.2020003805
- The paper
- Verkleij, C. P. M., Broekmans, M. E. C., van Duin, M., Frerichs, K. A., Kuiper, R., de Jonge, A. V., Kaiser, M., Morgan, G., Axel, A., Boominathan, R., Sendecki, J., Wong, A., Verona, R. I., Sonneveld, P., Zweegman, S., Adams, H. C., Mutis, T., & van de Donk, N. W. C. J. (2021). Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Advances. https://doi.org/10.1182/bloodadvances.2020003805
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.